Sangamo BioSciences | SGMO - Операционные расходы





Операционные расходы Изменить Дата
Alaunos Therapeutics USD 1.19M 148K 2025-09
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amgen USD 4.78B 1.12B 2026-03
Bayer EUR 10.33B 126M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cipla INR 60.98B 1.06B 2025-12
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.29M 1.51M 2025-12
CSL USD 5.7B 2.82B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Grifols EUR 1.99B 217.4M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Merck USD 18.17B 8.01B 2026-03
Novartis USD 9.29B 507M 2026-03
Omeros USD 59.16M 20.13M 2024-06
Pfizer USD 90.1B 77.19B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Tectonic Therapeutic USD 21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03